RecruitingPhase 1NCT07021157

A Study to Evaluate the Safety, Tolerability and PK of SK-08

A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Single-dose Increasing of SK-08 Tablets in Healthy Participants


Sponsor

Consun Pharmaceutical Group

Enrollment

48 participants

Start Date

Mar 9, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The trial is conducted in a single-center, randomized, double-blind, placebo-controlled, dose-increasing design. To evaluate the safety, tolerability, pharmacokinetics(PK) ,and pharmacodynamics (PD) characteristics of SK-08 in healthy participants.


Eligibility

Min Age: 18 YearsMax Age: 45 Years

Inclusion Criteria4

  • Healthy male and female participants aged 18 to 45 years (inclusive).
  • Male participants: Body weight ≥50 kg; Female participants: Body weight ≥45 kg; Body mass index (BMI) between 19.0 and 26 kg/m².
  • Participants must have no plans for conception during the trial and for 3 months after the last dose, and must voluntarily use effective contraception with no plans for sperm or egg donation .
  • Capable of understanding and voluntarily providing written informed consent prior to any study-related procedures.

Exclusion Criteria13

  • Have a specific history of allergies or have an allergic constitution;
  • Have a history of chronic diseases or severe diseases in the cardiovascular, liver, kidney, biliary tract, respiratory, blood and lymphatic, endocrine, immune, mental, neuromuscular, gastrointestinal systems, etc.
  • Developed acute diseases from 2 weeks before screening to before randomization ;
  • Patients with previous or current hypotension or insufficient blood volume, intracranial hypertension or cerebral hemorrhage, or those with ocular diseases (such as angle-closure glaucoma), who are not suitable for inclusion after assessment by the researcher;
  • Those with clinical significance hypokalemia, hyperkalemia, hypomagnesemia, hypermagnesemia, hypocalcemia, and hypercalcemia;
  • Those who have used any drugs or health supplements from 2 weeks before screening to randomization ;
  • Any drugs that may interact with this product have been used from 30 days before screening to randomization, such as CYP450 inhibitors or inducers ;
  • Those who have undergone major surgical operations from 6 months before screening , or who plan to undergo surgery during the study period, or who have undergone surgeries as judged by the investigator to affect drug absorption, distribution, metabolism, and excretion;
  • Those who have received live attenuated vaccine inoculation from 2 weeks before screening to randomization or those who need to receive live attenuated vaccine inoculation during the trial;
  • Those who had a history of alcohol abuse within one year before screening;
  • Those who smoked more than 5 cigarettes per day on average within 3 months before screening and before randomization, or were unable to stop using any tobacco products during the trial period;
  • Those who cannot tolerate venipuncture/indwelling needles or have a history of fainting from needles or blood ;
  • Other researchers determined that the subjects were not suitable to participate.

Interventions

DRUGSK-08

Dose groups of 5 mg, 7.5mg,12.5 mg, 30 mg, 45 mg, and 60 mg were given SK-08 once.

DRUGPlacebo

Dose groups of 5 mg, 7.5mg,12.5 mg, 30 mg, 45 mg, and 60 mg were given placebo once.


Locations(1)

The First Affiliated Hospital,Zhejiang University

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07021157


Related Trials